These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22579160)

  • 1. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.
    Emsley R; Oosthuizen PP; Koen L; Niehaus DJ; Martinez G
    J Clin Psychiatry; 2012 Apr; 73(4):e541-7. PubMed ID: 22579160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of treatment response in second-episode versus first-episode schizophrenia.
    Emsley R; Oosthuizen P; Koen L; Niehaus D; Martinez L
    J Clin Psychopharmacol; 2013 Feb; 33(1):80-3. PubMed ID: 23277247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia.
    Xiang YT; Wang CY; Ungvari GS; Kreyenbuhl JA; Chiu HF; Lai KY; Lee EH; Bo QJ; Dixon LB
    Pharmacopsychiatry; 2011 Jun; 44(4):135-41. PubMed ID: 21710403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia.
    Lee MS; Ko YH; Lee SH; Seo YJ; Kim SH; Joe SH; Han CS; Lee JH; Jung IK
    Hum Psychopharmacol; 2006 Aug; 21(6):399-407. PubMed ID: 16915580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct transition to long-acting risperidone--analysis of long-term efficacy.
    Kissling W; Heres S; Lloyd K; Sacchetti E; Bouhours P; Medori R; Llorca PM
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):15-21. PubMed ID: 16144782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
    Schmauss M; Diekamp B; Gerwe M; Schreiner A; Ibach B
    Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.
    Martin SD; Libretto SE; Pratt DJ; Brewin JS; Huq ZU; Saleh BT
    Curr Med Res Opin; 2003; 19(4):298-305. PubMed ID: 12841922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
    Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting risperidone improves negative symptoms in stable psychotic patients.
    Curtis VA; Katsafouros K; Möller HJ; Medori R; Sacchetti E
    J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.